REM Sleep Behavior Disorder
62
17
24
16
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.2%
2 terminated out of 62 trials
88.9%
+2.3% vs benchmark
8%
5 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 16 completed trials
Clinical Trials (62)
A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBD
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands
Neuroplasticity in RBD
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
5-HT RBD REM Sleep Behavior Disorder
MIBG in Aging and Neurologic Disorders
IMPACT 360 for Parkinson's Disease
Natural History Study of Synucleinopathies
The COSP-RBD Study: Concussions and Contact Sports in RBD vs Controls
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
Intestinal Immunity in Neurologic Disease
North American Prodromal Synucleinopathy Consortium Stage 2
A Multimodal Prospective Cohort Study of Parkinsonism
Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology
Unmet Needs Among Patients With Isolated REM Sleep Behavior Disorder (iRBD) and Their Significant Others
Parkinson's Disease Biomarker Study
Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder
DaTSCAN Imaging in Aging and Neurodegenerative Disease
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease